A prospective, exploratory, single-center clinical study for Anlotinib Hydrochloride combined with chemotherapy versus chemotherapy alone for advanced, recurrent, and persistent vaginal cancer, cervical cancer, and uterine malignancies
Latest Information Update: 25 Jun 2019
At a glance
- Drugs Catequentinib (Primary) ; Antineoplastics
- Indications Cervical cancer; Uterine diseases; Vulvovaginal cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Jun 2019 New trial record